Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China
· Delayed Price · Currency is CNY 22.28
-0.70 (-3.05%)
Jun 13, 2025, 2:45 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Biological Reagent | 943.66M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent Growth | -34.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostic Reagent | 248.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostic Reagent Growth | -87.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Technical Services | 59.59M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Technical Services Growth | -41.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostic Instrument | 20.77M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostic Instrument Growth | 32.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Materials and Other Materials | 11.26M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Business | 2.41M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Business Growth | -36.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Quantitative Polymerase Chain Reaction Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Quantitative Polymerase Chain Reaction Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point-of-care Testing Diagnostic Reagent - Colloidal Gold Immunochromatographic Reagent | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Polymerase Chain Reaction Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Polymerase Chain Reaction Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Gene Sequencing Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Gene Sequencing Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Reverse Transcription Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Reverse Transcription Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point-of-care Testing Diagnostic Reagent - Quantum Dot Immunofluorescence Reagent | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point-of-care Testing Diagnostic Reagent - Quantum Dot Immunofluorescence Reagent Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Molecular Cloning Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Molecular Cloning Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point-of-care Testing Diagnostic Reagent - Fluorescence Polymerase Chain Reaction Nucleic Acid Detection Reagent | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Extraction and Purification Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Extraction and Purification Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Cell/Protein Series | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Reagent - Cell/Protein Series Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point-of-care Testing Diagnostic Equipment | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| China | 1.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | -69.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas | 34.31M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas Growth | -85.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|